DRUG · Mapped RxNorm record
Paclitaxel
Normalized identity: paclitaxelView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Eribulin Plus Gemcitabine (EG) vs Paclitaxel Plus Gemcitabine (PG) in HER2-Negative Metastatic Breast Cancer
NCT02263495
Drugs and interventions used in this trial
3 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Eribulin
Normalized identity: eribulinView linked drug · Find medicine records ·
Find other trials using this name
DRUG · Mapped RxNorm record
Gemcitabine
Normalized identity: gemcitabineView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedEribulin Plus Gemcitabine (EG) vs Paclitaxel Plus Gemcitabine (PG) in HER2-Negative Metastatic Breast Cancer
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Metastatic Breast Cancerunresolved
Interventions
PaclitaxelDRUG · verified · RxNorm: paclitaxel
EribulinDRUG · verified · RxNorm: eribulin
GemcitabineDRUG · verified · RxNorm: gemcitabine
Sponsors & collaborators
Asan Medical Centerlead sponsor
Eisai Inc.collaborator
Dong-A ST Co., Ltd.collaborator
Samyang Biopharmaceuticals Corporationcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02263495 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.